05-Jun-2012 By Nick Taylor
Cetero Research posted a $3.1m (€2.5m) net loss in April as FDA rework expenses and reorganisation costs dragged on earnings.
04-Jun-2012 By Nick Taylor
AptarGroup is buying Stelmi for €165m ($205m) to expand into primary packaging components for injectable delivery devices.
31-May-2012 By Nick Taylor
A FDA import alert drove a double-digit drop in quarterly cephalosporin sales at Aurobindo and led to a one-third cut in full year earnings.
16-May-2012 By Nick Taylor
Expiration of contract sales deals drove a 28 per cent drop in revenue at PDI and pushed financials below analysts’ expectations.
03-May-2012 By Nick Taylor
A doubling in the percentage of new clients buying more than one product helped Medidata beat first quarter expectations.
24-Apr-2012 By Nick Taylor
Icon posted double-digit year-on-year sales growth and an uptick, excluding one-off charges, in operating income.
12-Apr-2012 By Nick Taylor
Demand for insulin pens and ready-to-fill syringes helped Gerresheimer post double-digit first quarter sales growth and raise its outlook.
Stopping ‘turning away biz’ helps ERT grow sales in Q4
29-Feb-2012 By Nick Taylor
ERT ended 2011 on a high as its decision to stop ‘walking away from business’ helped it post double-digit sales growth.
20-Feb-2012 By Nick Taylor
West Pharmaceutical Services posted another flat quarter of proprietary delivery product sales but is predicting “notable increases” in 2012.
16-Feb-2012 By Nick Taylor
Fourth quarter earnings at Icon missed analyst estimates and its guidance as an uptick in sales failed to offset rising costs.
09-Feb-2012 By Nick Taylor
AMPAC Fine Chemicals posted a 50 per cent jump in revenues after the return of sales from its antiviral business.
07-Feb-2012 By Gareth Macdonald
Foreign currency effects left Indian contractor Jubilant Life Sciences with a third quarter loss despite record sales.
31-Jan-2012 By Nick Taylor
Parexel posted double-digit revenue growth and record backlog in its second quarter, but rising costs drove down profits.
26-Jan-2012 By Nick Taylor
Covance is accelerating IT investment faster and for longer than expected, resulting in 2012 guidance that met analysts’ “worst-case fears”.
25-Jan-2012 By Nick Taylor
Lonza has fired its CEO after a halving of net income prompted the board to find another leader for “the challenging years ahead”.
21-Dec-2011 By Nick Taylor
BASi posted its first full year net profit since 2007, despite a fourth quarter loss, and is seeking to expand its services with acquisitions.
21-Dec-2011 By Gareth Macdonald
Warnex is to sell its analytical services division to an unnamed private company in the latest move in a drastic restructuring programme.
CRL’s preclinical arm will struggle, but RMS and strategic deals hold hope for 2012
13-Dec-2011 By Gareth Macdonald
Charles River Laboratories’ (CRL) preclinical division will continue to struggle in 2012 but the recent uptick in strategic partnership activity is a ray of hope according to a leading analyst.
ShangPharma opening facility dedicated to major customer
22-Nov-2011 By Nick Taylor
ShangPharma is opening a 100,000 sq ft facility dedicated to serving a big customer as it continues to strengthen ties to top clients.
SeraCare posts Q4 loss after bioservice revenue halves
21-Nov-2011 By Nick Taylor
SeraCare slipped into the red in the fourth quarter as loss of government business halved bioservice revenues.
Strategic outsourcing coming to EU packaging, United Drug says
16-Nov-2011 By Nick Taylor
United Drug plans to win strategic packaging relationships in Europe as biopharm companies cut fixed costs through outsourcing.
CryoPort posts widening loss after key client sales plummet
15-Nov-2011 By Nick Taylor
CryoPort posted a widening second quarter deficit after a client that accounted for close to half its revenues cutback.
Wuxi sees demand grow in Q3 underlining strength of China’s R&D sector
14-Nov-2011 By Gareth Macdonald
Wuxi Pharmatech posted a positive set of third-quarter financials, further underlining the current strength of China’s R&D services sector.
PDI operating profit falls as DCA buy drags on performance
10-Nov-2011 By Nick Taylor
Operating profit at PDI fell 90 per cent in the third quarter after the acquired digital communications unit again dragged on performance.
Contrasting early phase performance for CRL and Covance in Q3
08-Nov-2011 By Gareth Macdonald
Charles River Laboratories (CRL) continued to experience low demand for preclinical services in Q3, while Covance's early-phase business saw revenue growth.
Icon and Parexel earnings down on Pfizer deal hiring spree
02-Nov-2011 By Nick Taylor
Pfizer booked $340m with Icon and Parexel in the last quarter but profits dropped as the CROs hired 800 people to handle the work.
13-Oct-2011 By Gareth Macdonald
Another day, another prediction the contract research sector is set for growth in 2012 with new analysis suggesting ‘mature’ strategic deals and higher demand will drive earnings.
inVentiv plans Asian expansion
31-Aug-2011 By Nick Taylor
inVentiv Health is looking to expand operations in Japan, China and India after completing takeovers of i3 and PharmaNet.
Rise of Chinese pharma helps ShangPharma grow in Q2
23-Aug-2011 By Nick Taylor
China-based clients now account for 10 per cent of ShangPharma revenues after successive quarters of triple-digit sales growth.
Akela plans CMO buys after exiting development project
10-Aug-2011 By Nick Taylor
Akela Pharma is focusing on its CMO and expanding it through acquisitions after its partner exited their drug development programme.
eClinical results round-up
10-Aug-2011 By Nick Taylor
Outsourcing-Pharma presents a round-up of eClinical quarterly results, including financials from Medidata, Perceptive Informatics, ERT and BioClinica.
Charles River preclinical sales slump to 6-year low in Q2
03-Aug-2011 By Nick Taylor
Preclinical service revenue at Charles River slumped to its lowest level since 2005 in the second quarter, but margin gains helped earnings beat analysts’ estimates.
Covance Q2 soaring thanks to Sanofi acquisitions
28-Jul-2011 By Natalie Morrison
Covance’s Q2 results marked a hefty uptick in early stage operating income thanks to the sites it took from Sanofi.
PPD says income and revs grew in Q2 but analysts unconvinced
update
27-Jul-2011 By Gareth Macdonald
PPD posted an improved set of financials for Q2 days after announcing a review of its long-term plan and capital structure following speculation it was looking for a buyer.
Sartorius Stedim Biotech sees single-use gains in H1; North American revs dip
25-Jul-2011 By Gareth Macdonald
Sartorius Stedim Biotech (SSB) has revised its full year guidance after its range of single-use products drove revenue gains in the first half of 2011.
Rising costs hit Icon’s Q2 ahead of Pfizer deal hiring drive
20-Jul-2011 By Nick Taylor
Icon has posted a 40 per cent drop in operating income as an uptick in expenses dragged on second quarter results.
Plastic fantastic for Gerresheimer in Q2, tubular glass revs dip
13-Jul-2011 By Gareth Macdonald
Gerresheimer saw strong demand for plastic systems and moulded glassware in the second quarter fiscal 2011, while tubular glass revenue dipped slightly.
Biopharma revenues key to Pall’s Q3 gains
13-Jun-2011 By Gareth Macdonald
Sales to the biopharmaceutical sector drove revenue growth at Pall in third quarter fiscal 2011 and will be key to the firm’s future says CEO.
Neuland doubles Q4 operating profit on strong API sales
23-May-2011 By Nick Taylor
Neuland Laboratories doubled its operating profit in the fourth quarter, continuing the full year trend, as API sales improved.
Production quality control issues drag on Teva Q1 sales
12-May-2011 By Nick Taylor
Quality issues slowed first quarter revenue growth at Teva but, with one plant resuming shipping and another awaiting re-inspection, sales are expected to pick up.
WuXi posts strong Q1 results on lab services gains
11-May-2011 By Alexandria Pesic
Shanghai-based contract research organisation (CRO) WuXi PharmaTech has announced strong financial results for the first quarter, 2011.
Double-digit growth at Cambrex driven by API sales
09-May-2011 By Nick Taylor
Cambrex recorded double-digit sales growth in the first quarter as the API producer overcame problems it faced a year ago.
AMRI posts small Q1 loss but sees strong growth of manufacturing biz
05-May-2011 By Gareth Macdonald
Albany Molecular Research (AMRI) posted a modest net loss on costs and restructuring charges, but saw revenue grow considerably in the first quarter thanks to contracting business and royalties.
CRL profits up in Q1 on tax benefits but sales drop on falling demand
04-May-2011 By Gareth Macdonald
Tax benefit from the sale of its US Phase I business helped CRO Charles Rivers Laboratories (CRL) to grow profits in the first quarter despite falling revenues and low demand.
Parexel cuts guidance & Phase I capacity after weak results
03-May-2011 By Nick Taylor
Parexel has slashed its guidance and is cutting early phase capacity after weak results, but hiring in other areas is accelerating.
Strong clinical development revs offset PPD lab cancellations
27-Apr-2011 By Nick Taylor
Laboratory service cancellations impacted PPD in the first quarter but strong clinical development performance kept results in line with expectations.
Novartis invests in Chinese vaccine maker
28-Mar-2011 By Gareth Macdonald
Novartis has acquired a majority stake in vaccine maker Zhejiang Tianyuan Bio-Pharmaceutical, continuing its efforts to accelerate revenue growth in China.
Cyprotex targets US to build on 2010 revenue growth
23-Mar-2011 By Nick Taylor
Cyprotex posted double-digit revenue growth in 2010 and expects the upwards trend to continue as it benefits from its US acquisition.
ShangPharma revs up in Q4, but margins narrow
21-Mar-2011 By Gareth Macdonald
ShangPharma said it saw revenue climb on higher customer spending in the fourth quarter, but that margins slid due to currency effects and higher share-based compensation.
Biopharma key to Pall’s Q2 gains
16-Mar-2011 By Gareth Macdonald
Life sciences drove Pall’s growth in the second quarter of fiscal 2011, with sales to the biopharmaceuticals sector making the biggest gains.
